ANTI-SARS-COV-1/2 S PROTEIN CR3022 ZOOMAB HUMAN MONOCLONAL

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.

Specificity

CR3022 is a ZooMAb human recombinant monoclonal antibody expressed in HEK293 cells that specifically detects SARS-CoV-1/2 Spike protein. It targets an epitope within the N-terminal half, S1 domain.

Immunogen

Recombinant fragment corresponding to the extracellular domain from SARS-CoV virus spike protein. (CR3022 is an antibody that was originally derived from a SARS-CoV-1-infected patient).

Application

Quality Control Testing

Western Blot Analysis: A 1:1,000 dilution of this antibody detected Rac1 in Rat Brain Microsomes.

Tested applications

Western Blot Analysis: A 1:1,000 dilution from a representative lot detected Rac1 in A431, HeLa, and NIH3T3 cell lysates.

Immunohistochemistry (Paraffin) Analysis: A 1:100 silution from a representative lot detected Rac1 in human esophagus tissue sections.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Rac1 in HeLa, A431, HUVEC , and NIH 3T3 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-SARS-CoV-1/2 S protein CR3022, ZooMAb, Cat. No. ZHU1077, is a human recombinant monoclonal antibody that detects Spike protein from SARS-CoV-1 and -2 and tested for use in Affinity Binding Assay, ELISA, Flow Cytometry, Neutralizing, and Western Blot

Target description

SARS-CoV-1/2 Spike glycoprotein (UniProt: P59594/P0DTC2; also known as S glycoprotein, E2, Peplomer protein) is encoded by the S gene (Gene ID: 1489668/43740568) in SARS-CoV-1/2 virus. The SARS-CoV-2 is a positive-strand RNA virus that causes severe respiratory syndrome in human. The mature SARS-CoV-2 contains 4 structural proteins: Envelope (E), Membrane (M), Nucleocapsid (N), and the Spike protein (S). E and M proteins help in viral assembly and N protein is needed for RNA synthesis. The S protein is a single-pass type I, homotrimeric, membrane glycoprotein that is responsible for virus binding and entry into host cell. It is synthesized with a signal peptide (aa 1-12), which is subsequently cleaved off to generate the mature protein that contains an extracellular domain (aa 13-1213), a transmembrane domain (aa 1214-1234), and a cytoplasmic domain 1235-1273). The S protein is further processed into S1 (aa 13-685) and S2 (aa 686-1273) subunits by host cell furin. The presence of a furin polybasic cleavage site in S protein from SARS-CoV-2 sets it apart from S protein in SARS-CoV that possesses a monobasic S1/S2 cleavage site. The S1 subunit has the receptor binding domain (RBD; aa 319-541) that mediates entry of SARS-CoV-2 into sensitive cells through the peptidase domain of host Angiotensin-converting enzyme 2 (ACE2) with high affinity (KD = 15 nM). The S2 protein, which is reported to be well conserved, is responsible for membrane fusion. CR3022 binds tightly to RBD of the SARS-CoV-2 spike protein at a site different to that used by the receptor. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Huo, J., et al. (2020). Cell Host & Microbe 28(3); 445-454; Ou, X., et al. (2020). Nat. Commun. 11(1); 1620; Shang, J., et al. (2020). Proc. Natl. Acad. Sci. USA. 117(21); 11727-11734).

Physical form

Purified human monoclonal antibody IgG1 in buffer containing PBS with 5% Trehalose without preservatives , normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

Reconstitution

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Data presented are the full extent of available current product information and are provided as-is. This product has not been tested or verified in any additional applications, sample types, including clinical and/or patient samples. Experimental conditions must be empirically derived by the user. Our Antibody Guarantee only covers tested suitable applications and conditions presented in our product information, and is not extended to publications.